

Recommendations of the SEC (Analgesic & Rheumatology) made in its 100th meeting held on 05.09.2023 at CDSCO (HQ), New Delhi:

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
SND Division			
1.	SND/MA/23/000005 Methadone Oral Solution 1 mg/ml	M/s. Rusan Pharma Ltd.	The firm didn't turn up for presentation.
GCT Division			
2.	CT/58/23 Online Submission (37792) J3P-MC-FTAFC01	M/s. Elli-Lilly	The firm presented Phase 2a/2b clinical trial protocol number: J3P-MC-FTAF, Amendment number: a before the committee. After detailed deliberation, the committee recommended for grant of permission to conduct the study as presented by firm
3.	CT/81/23 Online Submission (38381) PF-66823859	M/s. Pfizer	The firm presented Phase III clinical trial protocol number:C0251006, Final Protocol Amendment 1, dated 11 May 2023 before the committee. After detailed deliberation, the committee recommended for grant of permission to conduct the study as presented by firm.
4.	CT/55/23 Online Submission (37579) ESK-001	M/s. Inventive International	The firm presented Phase II clinical trial protocol number: ESK-001-010, Original Version 3,dated 08 February 2023 before the committee. After detailed deliberation, the committee recommended for grant of permission to conduct the study as presented by firm